Cover Image
市場調查報告書

InteRNA Technologies B.V.:產品平台分析

InteRNA Technologies B.V. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 289822
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
InteRNA Technologies B.V.:產品平台分析 InteRNA Technologies B.V. - Product Pipeline Review - 2015
出版日期: 2015年06月24日 內容資訊: 英文 24 Pages
簡介

InteRNA Technologies B.V.是創藥開發企業,致力於開發基於自家公司獨家的微RNA運作的癌症治療藥。該公司的目標在於提升miRNA排列的翻譯技術,與開發關係到信號轉換途徑的遺傳基因之治療藥

本報告提供Quantum Pharmaceuticals的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

InteRNA Technologies B.V.的基本資料

  • InteRNA Technologies B.V.概要
  • 主要資訊
  • 企業資料

InteRNA Technologies B.V.:R&D概要

  • 主要的治療範圍

InteRNA Technologies B.V.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

InteRNA Technologies B.V.:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

InteRNA Technologies B.V.:藥物簡介

  • MicroRNA for GBM and Renal Cell cancer
  • miRNA-3157
  • MicroRNA to Inhibit Mutated Ataxia Telangiectasia Gene for Head and Neck Cancer
  • MicroRNAs for Neurodegenerative Diseases
  • miRNA for Cancer

InteRNA Technologies B.V.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

InteRNA Technologies B.V.:最近的開發平台趨勢

InteRNA Technologies B.V.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07234CDB

Summary

Global Markets Direct's, 'InteRNA Technologies B.V. - Product Pipeline Review - 2015', provides an overview of the InteRNA Technologies B.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of InteRNA Technologies B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of InteRNA Technologies B.V. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of InteRNA Technologies B.V.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the InteRNA Technologies B.V.'s pipeline products

Reasons to buy

  • Evaluate InteRNA Technologies B.V.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of InteRNA Technologies B.V. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the InteRNA Technologies B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of InteRNA Technologies B.V. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of InteRNA Technologies B.V.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of InteRNA Technologies B.V. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • InteRNA Technologies B.V. Snapshot
    • InteRNA Technologies B.V. Overview
    • Key Information
    • Key Facts
  • InteRNA Technologies B.V. - Research and Development Overview
    • Key Therapeutic Areas
  • InteRNA Technologies B.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • InteRNA Technologies B.V. - Pipeline Products Glance
    • InteRNA Technologies B.V. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • InteRNA Technologies B.V. - Drug Profiles
    • MicroRNA-7 for GBM and Renal Cell cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miRNA-3157
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MicroRNAs for Neurodegenerative Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miRNA for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miRNA to Inhibit Mutated Ataxia Telangiectasia Gene for Head and Neck Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • InteRNA Technologies B.V. - Pipeline Analysis
    • InteRNA Technologies B.V. - Pipeline Products by Target
    • InteRNA Technologies B.V. - Pipeline Products by Molecule Type
    • InteRNA Technologies B.V. - Pipeline Products by Mechanism of Action
  • InteRNA Technologies B.V. - Recent Pipeline Updates
  • InteRNA Technologies B.V. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • InteRNA Technologies B.V., Key Information
  • InteRNA Technologies B.V., Key Facts
  • InteRNA Technologies B.V. - Pipeline by Indication, 2015
  • InteRNA Technologies B.V. - Pipeline by Stage of Development, 2015
  • InteRNA Technologies B.V. - Monotherapy Products in Pipeline, 2015
  • InteRNA Technologies B.V. - Partnered Products in Pipeline, 2015
  • InteRNA Technologies B.V. - Partnered Products/ Combination Treatment Modalities, 2015
  • InteRNA Technologies B.V. - Preclinical, 2015
  • InteRNA Technologies B.V. - Discovery, 2015
  • InteRNA Technologies B.V. - Pipeline by Target, 2015
  • InteRNA Technologies B.V. - Pipeline by Molecule Type, 2015
  • InteRNA Technologies B.V. - Pipeline Products by Mechanism of Action, 2015
  • InteRNA Technologies B.V. - Recent Pipeline Updates, 2015
  • InteRNA Technologies B.V., Other Locations

List of Figures

  • InteRNA Technologies B.V. - Pipeline by Top 10 Indication, 2015
  • InteRNA Technologies B.V. - Pipeline by Stage of Development, 2015
  • InteRNA Technologies B.V. - Monotherapy Products in Pipeline, 2015
  • InteRNA Technologies B.V. - Partnered Products in Pipeline, 2015
  • InteRNA Technologies B.V. - Pipeline by Top 10 Molecule Type, 2015
Back to Top